Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Compared to the control group, for the breast cancer group, mean 25-OH vitamin D levels were lower (48.6 ± 18.8 vs. 53.8 ± 29.0; p = 0.017); and a higher proportion had a vitamin D level below 50 nmol/L (54.4% and 46.3%) (p = 0.071).Baseline characteristics of the breast cancer and control groups.GroupBreast cancer n = 284Control n = 284p-valueAge0.834Mean ± SD58.8 ± 10.558.6 ± 9.5Median (Q1,Q3)60.5 (51,72.5)60 (53,65)Range30: 8326 to 79BMI mean ± SD28.1 ± 5.027.6 ± 4.60.201HRT use n (%)78 (27.5%)78 (27.5%)1.0Parity median (Q1, Q3)3 (2,4)3 (2,4)0.038Mean ± SD2.8 ± 1.43.0 ± 1.1Ethnicity n (%)0.015 Jewish277 (97.5%)284 (100.0%) Bedouin7 (2.5%)0 (0.0%)Treatment for osteoporosis in the 2 years before enrollmenta Oral bisphosphonates n (%)13 (6.6%)15 (5.4%)0.694 Injected bisphosphonates n (%)2 (1.0%)1 (0.4%)0.380 Bisphosphonates (any) n (%)15 (7.6%)16 (5.8%)0.456Treatment with Vitamin D/Ca supplements n (%)94 (47.5%)145 (52.5%)0.306Lab results at enrollmentCreatinine (mg/dL)0.308Mean ± SD0.69 ± 0.160.70 ± 0.13n available data281277eGFR (MDRD calc; mL/min/1.73 m²) mean ± SD98.7 ± 23.495.1 ± 20.30.053PTH (pg/mL) mean ± SD53.0 ± 28.855.2 ± 24.80.358n available data254260(OH)25-Vitamin D (nmol/L) mean ± SD48.9 ± 19.053.8 ± 28.80.022n available data261268(OH)25-Vitamin D < 50(nmol/L) n (%)142 (54.4%)124 (46.3%)0.068BMI body mass index, HRT hormone replacement therapy, eGFR estimated glomerular filtration rate, PTH parathyroid hormone.aUsed drug distribution data for both sub groups, % of Clalit insurees is shown.

Source: Study population. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study

Source: Article title.

Women were recruited at their first visit to the oncology department following surgery for breast cancer.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study

Cohort study · NPJ Breast Cancer · 2022

Original publication title

Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study

Merav Fraenkel; Victor Novack; Yuval Mizrakli; Michael Koretz; Ethel Siris; Larry Norton; Tali Shafat; David B. Geffen

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Estrogen may have opposing effects on health, namely increasing the risk of breast cancer and improving bone health by increasing bone mineral density (BMD). The objective of this study was to compare dual-energy X-ray absorptiometry (DXA) BMD between women newly diagnosed with breast cancer and matched controls without breast cancer. Women newly diagnosed with breast cancer treated between April 2012 and October 2017 were prospectively enrolled. A control group was established of women with negative mammography or breast ultrasound, matched 1:1 by age, body mass index, parity, and the use of hormone replacement therapy.

All those included had DXA BMD, and lab assessments at enrollment. Of 869 women with newly diagnosed breast cancer, 464 signed informed consent. Of the 344 who completed the study protocol, 284 were matched to controls. Overall, the mean age was 58 years. Compared to the control group, for the breast cancer group, the mean vitamin D level was lower (48.9 ± 19.0 vs. 53.8 ± 28.8 nmol/L, p = 0.022); and mean values were higher of total hip BMD (0.95 ± 0.14 vs. 0.92 ± 0.12 g/cm2, p = 0.002), T score (−0.38 ± 1.17 vs. −0.68 ± 0.98, p = 0.002), and Z score (0.32 ± 1.09 vs. 0.01 ± 0.88, p < 0.001).

Among the women with breast cancer, no correlations were found of baseline BMD with tumor size or grade, nodal involvement, or breast cancer stage. We concluded that women with newly diagnosed breast cancer tend to have higher BMD than women with similar characteristics but without breast cancer. This implies that BMD might be considered a biomarker for breast cancer risk.

Authors’ abstract

Estrogen may have opposing effects on health, namely increasing the risk of breast cancer and improving bone health by increasing bone mineral density (BMD). The objective of this study was to compare dual-energy X-ray absorptiometry (DXA) BMD between women newly diagnosed with breast cancer and matched controls without breast cancer. Women newly diagnosed with breast cancer treated between April 2012 and October 2017 were prospectively enrolled. A control group was established of women with negative mammography or breast ultrasound, matched 1:1 by age, body mass index, parity, and the use of hormone replacement therapy.

All those included had DXA BMD, and lab assessments at enrollment. Of 869 women with newly diagnosed breast cancer, 464 signed informed consent. Of the 344 who completed the study protocol, 284 were matched to controls. Overall, the mean age was 58 years. Compared to the control group, for the breast cancer group, the mean vitamin D level was lower (48.9 ± 19.0 vs. 53.8 ± 28.8 nmol/L, p = 0.022); and mean values were higher of total hip BMD (0.95 ± 0.14 vs. 0.92 ± 0.12 g/cm2, p = 0.002), T score (−0.38 ± 1.17 vs. −0.68 ± 0.98, p = 0.002), and Z score (0.32 ± 1.09 vs. 0.01 ± 0.88, p < 0.001).

Among the women with breast cancer, no correlations were found of baseline BMD with tumor size or grade, nodal involvement, or breast cancer stage. We concluded that women with newly diagnosed breast cancer tend to have higher BMD than women with similar characteristics but without breast cancer. This implies that BMD might be considered a biomarker for breast cancer risk.

Publication and source details

Original title: Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study

Merav Fraenkel; Victor Novack; Yuval Mizrakli; Michael Koretz; Ethel Siris; Larry Norton; Tali Shafat; David B. Geffen

NPJ Breast Cancer · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Cure Breast Cancer Foundation in the United States

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T10:51:26.108670+00:00

DOI: 10.1038/s41523-022-00388-z · PMC8854387